[1] 叶胜龙. 2012年肝癌领域研究进展.中华肝脏病杂志,2013,21:167-169.
[2] Chen Z, Xiao HE, Ramchandra P, et al. Imaging and pathological features of primary hepatic neuroendocrine carcinoma: An analysis of nine cases and review of the literature. Oncol Lett, 2014, 7:956-962.
[3] 赵运胜,王猛,崔辰莹,等.评价8种血清标志物在原发性肝癌诊断中的临床价值.重庆医学,2014, 43:214-216.
[4] 周琦,张琼,魏来,等.血清甲胎蛋白、肿瘤相关物质和癌胚抗原对原发性肝癌的鉴别诊断.世界华人消化杂志,2010,18:1936-1939.
[5] 席强,孙桂荣,丛培珊,等.血清异常凝血酶原和甲胎蛋白联合检测对原发性肝癌的临床价值.中华检验医学杂志,2014,37:928-932.
[6] 中华人民共和国卫生部(卫办医政发[2011]121号). 原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志,2011,16:929-946.
[7] 向启云,谢传英,董艳娥,等.8种血清标志物对肝癌的诊断价值.实用癌症杂志,2015, 30: 348-351.
[8] Kang SH, Kim DY, Jeon SM, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-Ⅱ levels. Eur J Gastroenterol Hepatol, 2012, 24:849-856.
[9] Kamel MM, Saad MF, Mahmoud AA, et al. Evaluation of serum PIVKA-Ⅱ and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma. Microb Pathog, 2014, 77:31-35.
[10] 孙华宝,叶德强,曹立,等. Logistic回归和ROC曲线评价8种原发性肝癌实验室诊断指标的临床价值.广东医学,2010,31:2650-2653.
[11] Park H, Park JY. Clinical significance of AFP and PIVKA-Ⅱ responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int, 2013, 2013: 310427.
[12] Potè N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-Ⅱ for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol, 2015, 62:848-854.
[13] Park JY, Lee MH, Choi GH, et al. 999 THE PROGNOSTIC ROLES OF PREOPERATIVE AFP AND PIVKA-Ⅱ IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING HEPATECTOMY (CURATIVE RESECTION). J Hepatol, 2011, 54:S397-S398.
[14] 钟志敏,王维,莫云丹,等.脱-γ-羧基凝血酶原对原发性肝癌的诊断价值探讨.检验医学,2013,28:382-386. |
